Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Bondronat
Bondronat 50 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 18
HOS-085659 · Präparat HOS-083171
H2-antagonists or other medicinal products that increase gastric pH.
In healthy male volunteers and postmenopausal women, intravenous ranitidine caused an increase in
ibandronic acid bioavailability of about 20% (which is within the normal variability of the
bioavailability of ibandronic acid), probably as a result of reduced gastric acidity. However, no dosage
adjustment is required when Bondronat is administered with H2-antagonists or medicinal products that
increase gastric pH.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-04-08T17:34:00Z · SHA-256 05636f81465a8a67f982eee4655be333acd7e9f5a20c04764f8127645519a0a1 · Passage 65893fa17d35953a6e9d9125ba6757da4c91e71782b9875df3645883d7e833e4 · Zeichen 1036–1521 im Abschnitt
Wechselwirkungen · Epivir
Epivir 150 mg film-coated tablets Epivir 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-085834 · Präparat HOS-083204
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) ranitidine (HOS-085660) cimetidine (HOS-085835) didanosine (HOS-085836) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 851–1387 im Abschnitt
Wechselwirkungen · Epivir
Epivir 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 21
HOS-085872 · Präparat HOS-083204
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) zidovudine (HOS-085837) trimethoprim (HOS-085184) ranitidine (HOS-085660) cimetidine (HOS-085835)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 851–1387 im Abschnitt
Wechselwirkungen · Hycamtin
HYCAMTIN 0.25 mg hard capsules HYCAMTIN 1 mg hard capsules · Abschnitt 4.5 · PDF-Seite 19
HOS-086088 · Präparat HOS-083256
The pharmacokinetics of topotecan were generally unchanged when co-administered with ranitidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-20T15:26:00Z · SHA-256 b5faba0cb8dc430e883615daec0cf15a62742b0008cf3a57c33ebf39c2a0a4b9 · Passage 8eba5b98f3045b4a0c9e4811e05789b51b4d4bfd5663a37de98cd63fa21745f1 · Zeichen 1600–1696 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 24
HOS-086344 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) ranitidine (HOS-085660) protease (HOS-085623) lopinavir (HOS-086269) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 3c27321459baa7b0705afde806e8b539a0a25a4b47e2383e187fb6fd8f60bfb2 · Zeichen 60628–61278 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56
HOS-086497 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) ranitidine (HOS-085660) protease (HOS-085623) lopinavir (HOS-086269) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 4de66caff969925d9ad024610386f020326d8902794177858246b69263b12d3c · Zeichen 62968–63646 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) fluconazole (HOS-087945) phenobarbital (HOS-085617) phenytoin (HOS-084531) valproic acid (HOS-088515) histamine (HOS-088516) ranitidine (HOS-085660) cimetidine (HOS-085835) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt
Wechselwirkungen · Temodal
Temodal 5 mg hard capsules Temodal 20 mg hard capsules Temodal 100 mg hard capsules Temodal 140 mg hard capsules Temodal 180 mg hard capsules Temodal 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-089540 · Präparat HOS-083877
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the
extent of absorption of temozolomide or the exposure to its active metabolite monomethyl
triazenoimidazole carboxamide (MTIC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T13:54:00Z · SHA-256 49a0026b6a071cadce495f46786dcd162d4d72e1fe7389385292e63aabdf9d0d · Passage ee289c2fa788917ac2b83776352d3a244ff18f6d1d1f0239d60402688d18e4d2 · Zeichen 0–230 im Abschnitt
Wechselwirkungen · Temodal
Temodal 2.5 mg/ml powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 26
HOS-089570 · Präparat HOS-083877
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the
extent of absorption of temozolomide or the exposure to its active metabolite monomethyl
triazenoimidazole carboxamide (MTIC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T13:54:00Z · SHA-256 49a0026b6a071cadce495f46786dcd162d4d72e1fe7389385292e63aabdf9d0d · Passage ee289c2fa788917ac2b83776352d3a244ff18f6d1d1f0239d60402688d18e4d2 · Zeichen 0–230 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 100 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-089935 · Präparat HOS-083949
Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of
interactions with other medicinal products administered concurrently should be considered,
particularly when their main route of elimination is active renal secretion via the organic cationic
transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) ranitidine (HOS-085660) cimetidine (HOS-085835)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 1675843e9b8449c95d3864ada4cae5935a283fe89e2d5c43d4283e20e5dae000 · Zeichen 221–693 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 5 mg/ml oral solution. · Abschnitt 4.5 · PDF-Seite 21
HOS-089961 · Präparat HOS-083949
Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of
interactions with other medicinal products administered concurrently should be considered,
particularly when their main route of elimination is active renal secretion via the organic cationic
transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) ranitidine (HOS-085660) cimetidine (HOS-085835)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 1675843e9b8449c95d3864ada4cae5935a283fe89e2d5c43d4283e20e5dae000 · Zeichen 221–693 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-108566 · Präparat HOS-093047
Phenytoin/Abacavir Interaction not studied. Insufficient data to
recommend dosage
Potential to slightly decrease adjustment.
abacavir plasma concentrations
through UGT induction. Monitor phenytoin
Phenytoin/Lamivudine Interaction not studied. concentrations.
Phenytoin/Zidovudine Phenytoin AUC
Valproic acid/Abacavir Interaction not studied.
As only limited data are
Valproic acid/Lamivudine available the clinical
Interaction not studied.
Valproic acid/Zidovudine Zidovudine AUC 80%significance is not known.
(250 mg or 500 mg thrice Monitor for signs of
daily/100 mg thrice daily)
(UGT inhibition) zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H2 RECEPTOR ANTAGONISTS)
Ranitidine/Abacavir Interaction not studied. No dosage adjustment
Ranitidine/Lamivudine Interaction not studied. necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) valproic acid (HOS-088515) histamine (HOS-088516) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 409c5f9ee2c015f2b6f723303036c2b2acdd238bc9098136b7a883f2d611ce36 · Zeichen 7108–8354 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-108567 · Präparat HOS-093047
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Abacavir Interaction not studied. No dosage adjustment
Cimetidine/Lamivudine Interaction not studied. necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660) cimetidine (HOS-085835)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage b85b7c4c80673a12dabf6f058474a31a8c27f45c1223b80106f055a5de934f2e · Zeichen 8385–8806 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12
HOS-108860 · Präparat HOS-093083
Lopinavir: ↔
Ranitidine (150 mg single Ranitidine: ↔ No dose adjustment necessary
dose)
Alpha1 adrenoreceptor antagonist
Alfuzosin Alfuzosin: Concomitant administration of
Due to CYP3A inhibition by Kaletra and alfuzosin is contra-
lopinavir/ritonavir, concentrations indicated (see section 4.3) as
of alfuzosin are expected to alfuzosin-related toxicity,
increase. including hypotension, may be
increased.
Analgesics
Fentanyl Fentanyl: Careful monitoring of adverse
Increased risk of side-effects effects (notably respiratory
(respiratory depression, sedation) depression but also sedation) is
due to higher plasma recommended when fentanyl is
concentrations because of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660) alfuzosin (HOS-086139) fentanyl (HOS-086196)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 96e190758dc45ac7fb4d963c731c6a1a9f40441a1d76efd2de728f20e2eab534 · Zeichen 7863–9031 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48–49
HOS-109005 · Präparat HOS-093083
48
(Lopinavir/ritonavir resulted in a higher incidence of
400/100 mg BID) gastrointestinal adverse events and
elevations in triglycerides with the
or combination regimen without
increases in virological efficacy,
Fosamprenavir when compared with standard doses
(1400 mg BID) of fosamprenavir/ritonavir.
Concomitant administration of these
(Lopinavir/ritonavir medicinal products is not
533/133 mg BID) recommended.
Kaletra must not be administered
once daily in combination with
amprenavir.
Tipranavir/ritonavir Lopinavir: Concomitant administration of these
(500/100 mg BID) AUC: ↓ 55% medicinal products is not
Cmin: ↓ 70% recommended.
Cmax: ↓ 47%
Acid reducing agents
Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary
QD)
Lopinavir: ↔
Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary
single dose)
Alpha1 adrenoreceptor antagonist
Alfuzosin Alfuzosin: Concomitant administration of
Due to CYP3A inhibition by Kaletra and alfuzosin is contra-
lopinavir/ritonavir, concentrations indicated (see section 4.3) as
of alfuzosin are expected to alfuzosin-related toxicity, including
increase. hypotension, may be increased.
Analgesics
Fentanyl Fentanyl: Careful monitoring of adverse effects
Increased risk of side-effects (notably respiratory depression but
(respiratory depression, sedation) also sedation) is recommended when
due to higher plasma fentanyl is concomitantly
concentrations because of administered with Kaletra.
CYP3A4 inhibition by
lopinavir/ritonavir.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fentanyl (HOS-086196) ranolazine (HOS-086141) fosamprenavir (HOS-086182) amprenavir (HOS-086183) tipranavir (HOS-086184) omeprazole (HOS-085912) ranitidine (HOS-085660) alfuzosin (HOS-086139)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 36be30eaedda7aebc321ed321c96a33a8b5f0e47dfdc414ad4d6358ff3954c0c · Zeichen 6614–9803 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 83–84
HOS-109078 · Präparat HOS-093083
83
Maraviroc Maraviroc: The dose of maraviroc should be
AUC: ↑ 295% decreased to 150 mg twice daily
Cmax: ↑ 97% during co-administration with
Due to CYP3A inhibition by Kaletra 400/100 mg twice daily.
lopinavir/ritonavir.
Integrase inhibitor
Raltegravir Raltegravir: No dose adjustment necessary
AUC: ↔
Cmax: ↔
C12: ↓ 30%
Lopinavir: ↔
Co-administration with other HIV protease inhibitors (PIs)
According to current treatment guidelines, dual therapy with protease inhibitors is generally not
recommended.
Fosamprenavir/ Fosamprenavir: Co-administration of increased
ritonavir (700/100 mg Amprenavir concentrations are doses of fosamprenavir (1400 mg
BID) significantly reduced. BID) with Kaletra oral solution
(533/133 mg BID) to protease
(Lopinavir/ritonavir inhibitor-experienced patients
400/100 mg BID) resulted in a higher incidence of
gastrointestinal adverse events and
or elevations in triglycerides with the
combination regimen without
Fosamprenavir increases in virological efficacy,
(1400 mg BID) when compared with standard doses
of fosamprenavir/ritonavir.
(Lopinavir/ritonavir Concomitant administration of these
533/133 mg BID) medicinal products is not
recommended.
Kaletra must not be administered
once daily in combination with
amprenavir.
Tipranavir/ritonavir Lopinavir: Concomitant administration of these
(500/100 mg BID) AUC: ↓ 55% medicinal products is not
Cmin: ↓ 70% recommended.
Cmax: ↓ 47%
Acid reducing agents
Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary
QD)
Lopinavir: ↔
Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary
single dose)
Alpha1 adrenoreceptor antagonist
Alfuzosin Alfuzosin: Concomitant administration of
Due to CYP3A inhibition by Kaletra and alfuzosin is contra-
lopinavir/ritonavir, concentrations indicated (see section 4.3) as
of alfuzosin are expected to alfuzosin-related toxicity, including
increase. hypotension, may be increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) maraviroc (HOS-086186) raltegravir (HOS-086187) protease (HOS-085623) fosamprenavir (HOS-086182) amprenavir (HOS-086183) tipranavir (HOS-086184) omeprazole (HOS-085912) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 262bfc7747e8af6a0bc31322576cc9f33731bdf23847197000d08285e923bde2 · Zeichen 5337–8975 im Abschnitt
Wechselwirkungen · Axura
Axura 10 mg film-coated tablets Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets Axura 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-109260 · Präparat HOS-093165
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dantrolene (HOS-109261) baclofen (HOS-089065) amantadine (HOS-086615) ketamine (HOS-109264) dextromethorphan (HOS-109265) phenytoin (HOS-084531) cimetidine (HOS-085835) ranitidine (HOS-085660) procainamide (HOS-086617) quinidine (HOS-085593) quinine (HOS-086616) nicotine (HOS-109269) hydrochlorothiazide (HOS-086937) warfarin (HOS-085950) prothrombin (HOS-085093)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:43:00Z · SHA-256 f6f4d5233129ccc09d7b126c13573858c875ee45f87e7bb2987c68026bf63a30 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Wechselwirkungen · Axura
Axura 5 mg/pump actuation, oral solution · Abschnitt 4.5 · PDF-Seite 15
HOS-109291 · Präparat HOS-093165
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nicotine (HOS-109269) hydrochlorothiazide (HOS-086937) warfarin (HOS-085950) prothrombin (HOS-085093) dantrolene (HOS-109261) baclofen (HOS-089065) amantadine (HOS-086615) ketamine (HOS-109264) dextromethorphan (HOS-109265) phenytoin (HOS-084531) cimetidine (HOS-085835) ranitidine (HOS-085660) procainamide (HOS-086617) quinidine (HOS-085593) quinine (HOS-086616)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:43:00Z · SHA-256 f6f4d5233129ccc09d7b126c13573858c875ee45f87e7bb2987c68026bf63a30 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-109442 · Präparat HOS-093201
Medicinal product Interaction Recommendations concerning
geometric mean changes (%) coadministration
Antacids
Cimetidine (400 mg BID) Voriconazole Cmax 18% No dose adjustment
[non-specific CYP450 inhibitor Voriconazole AUC 23%
and increases gastric pH]
Omeprazole (40 mg QD)* Omeprazole Cmax 116% No dose adjustment of
[CYP2C19 inhibitor; Omeprazole AUC 280% voriconazole is recommended.
CYP2C19 and CYP3A4 Voriconazole Cmax 15%
substrate] Voriconazole AUC 41% When initiating voriconazole in
patients already receiving
Other proton pump inhibitors omeprazole doses of 40 mg or
that are CYP2C19 substrates above, it is recommended that
may also be inhibited by the omeprazole dose be halved.
voriconazole and may result in
increased plasma concentrations
of these medicinal products.
Ranitidine (150 mg BID) Voriconazole Cmax and AUC ↔ No dose adjustment
[increases gastric pH]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) omeprazole (HOS-085912) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage a964e1dd69cbc5960da5e707c3bb5a0af698c9648ed7477b2b8dc2f453d44a4f · Zeichen 2057–3491 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 42
HOS-109534 · Präparat HOS-093201
Medicinal product Interaction Recommendations concerning
geometric mean changes (%) coadministration
Antacids
Cimetidine (400 mg BID) Voriconazole Cmax 18% No dose adjustment
[non-specific CYP450 inhibitor Voriconazole AUC 23%
and increases gastric pH]
Omeprazole (40 mg QD)* Omeprazole Cmax 116% No dose adjustment of
[CYP2C19 inhibitor; Omeprazole AUC 280% voriconazole is recommended.
CYP2C19 and CYP3A4 Voriconazole Cmax 15%
substrate] Voriconazole AUC 41% When initiating voriconazole in
patients already receiving
Other proton pump inhibitors omeprazole doses of 40 mg or
that are CYP2C19 substrates above, it is recommended that
may also be inhibited by the omeprazole dose be halved.
voriconazole and may result in
increased plasma concentrations
of these medicinal products.
Ranitidine (150 mg BID) Voriconazole Cmax and AUC ↔ No dose adjustment
[increases gastric pH]
Antiarrhythmics
Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment
[P-gp substrate] Digoxin AUC ↔
Quinidine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of quinidine 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Antibacterials
Flucloxacillin Significantly decreased plasma If concomitant administration of
[CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin
been reported. cannot be avoided, monitor for
potential loss of voriconazole
effectiveness (e.g., by therapeutic
drug monitoring); increasing the
dose of voriconazole may be
needed.
Macrolide antibiotics No dose adjustment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) omeprazole (HOS-085912) ranitidine (HOS-085660) digoxin (HOS-086172) quinidine (HOS-085593) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 534b27e000563107a8bd6c73d67131e3dbf51bbeeb2ec364adce0f84e9ccd348 · Zeichen 2117–4967 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.